{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:53Z","timestamp":1788570533684,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PDRadiopharma Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Amyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid PET imaging is still under investigation. The aim of this study was to evaluate the diagnostic impact and clinical utility in patient management of amyloid PET using <jats:sup>18<\/jats:sup>F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease (AD). We also aimed to determine the cutoffs for amyloid positivity for quantitative measures by investigating the agreement between quantitative and visual assessments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ninety-nine patients suspected of having AD underwent <jats:sup>18<\/jats:sup>F-florbetapir PET at five institutions. Site-specialized physicians provided a diagnosis of AD or non-AD with a percentage estimate of their confidence and their plan for patient management in terms of medication, prescription dosage, additional diagnostic tests, and care planning both before and after receiving the amyloid imaging results. A PET image for each patient was visually assessed and dichotomously rated as either amyloid-positive or amyloid-negative by four board-certified nuclear medicine physicians. The PET images were also quantitatively analyzed using the standardized uptake value ratio (SUVR) and Centiloid (CL) scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Visual interpretation obtained 48 positive and 51 negative PET scans. The amyloid PET results changed the AD and non-AD diagnosis in 39 of 99 patients (39.3%). The change rates of 26 of the 54 patients (48.1%) with a pre-scan AD diagnosis were significantly higher than those of 13 of the 45 patients with a pre-scan non-AD diagnosis (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20095.334, <jats:italic>p<\/jats:italic>\u2009=\u20090.0209). Amyloid PET results also resulted in at least one change to the patient management plan in 42 patients (42%), mainly medication (20 patients, 20%) and care planning (25 patients, 25%). Receiver-operating characteristic analysis determined the best agreement of the quantitative assessments and visual interpretation of PET scans to have an area under the curve of 0.993 at an SUVR of 1.19 and CL of 25.9.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Amyloid PET using <jats:sup>18<\/jats:sup>F-florbetapir PET had a substantial clinical impact on AD and non-AD diagnosis and on patient management by enhancing diagnostic confidence. In addition, the quantitative measures may improve the visual interpretation of amyloid positivity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-022-01792-y","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T10:03:33Z","timestamp":1664877813000},"page":"1039-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-9897","authenticated-orcid":false,"given":"Hiroshi","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Sanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Tomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Tachimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"issue":"6","key":"1792_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.109.069088","volume":"51","author":"DF Wong","year":"2010","unstructured":"Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51(6):913\u201320. https:\/\/doi.org\/10.2967\/jnumed.109.069088.","journal-title":"J Nucl Med"},{"issue":"3","key":"1792_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Florbetapir F 18 study investigators performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer\u2019s disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378\u201384.","journal-title":"J Nucl Med"},{"issue":"11","key":"1792_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.185017.","journal-title":"J Nucl Med"},{"issue":"19","key":"1792_CR4","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939\u201349. https:\/\/doi.org\/10.1001\/jama.2015.4669.","journal-title":"JAMA"},{"issue":"1","key":"1792_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WAD.0b013e318279d02a","volume":"27","author":"M Grundman","year":"2013","unstructured":"Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4\u201315. https:\/\/doi.org\/10.1097\/WAD.0b013e318279d02a.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1792_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-9-10","volume":"9","author":"EM Mitsis","year":"2014","unstructured":"Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, et al. A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10. https:\/\/doi.org\/10.1186\/1750-1326-9-10.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"1792_CR7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JAD-160302","volume":"54","author":"PS Weston","year":"2016","unstructured":"Weston PS, Paterson RW, Dickson J, Barnes A, Bomanji JB, Kayani I, et al. Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid? J Alzheimers Dis. 2016;54(4):1297\u2013302. https:\/\/doi.org\/10.3233\/JAD-160302.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1792_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2. https:\/\/doi.org\/10.1186\/s13195-016-0228-4.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1792_CR9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3233\/JAD-151180","volume":"52","author":"MR Bensa\u00efdane","year":"2016","unstructured":"Bensa\u00efdane MR, Beauregard JM, Poulin S, Buteau FA, Guimond J, Bergeron D, et al. Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016;52(4):1251\u201362. https:\/\/doi.org\/10.3233\/JAD-151180.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1792_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1159\/000345783","volume":"2","author":"KS Frederiksen","year":"2012","unstructured":"Frederiksen KS, Hasselbalch SG, Hejl AM, Law I, H\u00f8jgaard L, Waldemar G. Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra. 2012;2(1):610\u201321. https:\/\/doi.org\/10.1159\/000345783.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"12","key":"1792_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, et al. Incremental diagnostic value of amyloid PET with [18F]-Florbetapir (INDIA-FBP) working group. Assessment of the incremental diagnostic value of Florbetapir F 18 Imaging in patients with cognitive Impairment: the incremental diagnostic value of amyloid PET with [18F]-Florbetapir (INDIA-FBP) study. JAMA Neurol. 2016;73(12):1417\u201324. https:\/\/doi.org\/10.1001\/jamaneurol.2016.3751.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1792_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jnnp-2017-316194","volume":"89","author":"CJ Carswell","year":"2018","unstructured":"Carswell CJ, Win Z, Muckle K, Kennedy A, Waldman A, Dawe G, et al. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. J Neurol Neurosurg Psychiatry. 2018;89(3):294\u20139. https:\/\/doi.org\/10.1136\/jnnp-2017-316194.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"1792_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394. https:\/\/doi.org\/10.1001\/jama.2019.2000.","journal-title":"JAMA"},{"issue":"3","key":"1792_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","volume":"14","author":"M Ceccaldi","year":"2018","unstructured":"Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement. 2018;14(3):293\u2013305. https:\/\/doi.org\/10.1016\/j.jalz.2017.09.009.","journal-title":"Alzheimers Dement"},{"issue":"3\u20134","key":"1792_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000478007","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, et al. Effectiveness of florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord. 2017;44(3\u20134):129\u201343. https:\/\/doi.org\/10.1159\/000478007.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1\u20132","key":"1792_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000441139","volume":"41","author":"M Grundman","year":"2016","unstructured":"Grundman M, Johnson KA, Lu M, Siderowf A, Dell\u2019Agnello G, Arora AK, et al. Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria. Dement Geriatr Cogn Disord. 2016;41(1\u20132):80\u201392. https:\/\/doi.org\/10.1159\/000441139.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"1792_CR17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s00259-016-3591-2","volume":"44","author":"T Yamane","year":"2017","unstructured":"Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer\u2019s disease neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44(5):850\u20137. https:\/\/doi.org\/10.1007\/s00259-016-3591-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1792_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3174\/ajnr.A4281","volume":"36","author":"AP Nayate","year":"2015","unstructured":"Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, et al. Use of standardized uptake value ratios decreases interreader variability of [18F] florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol. 2015;36(7):1237\u201344. https:\/\/doi.org\/10.3174\/ajnr.A4281.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"1792_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1792_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","volume":"14","author":"M Navitsky","year":"2018","unstructured":"Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the centiloid scale. Alzheimers Dement. 2018;14(12):1565\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1353.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1792_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"3","key":"1792_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"1792_CR23","doi-asserted-by":"crossref","unstructured":"American psychiatric association [APA]. Diagnostic and statistical manual of mental disorders (DSM-5). Washington DC: American Psychiatric Association.2013","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"1792_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40658-016-0159-y","volume":"3","author":"Y Ikari","year":"2016","unstructured":"Ikari Y, Akamatsu G, Nishio T, Ishii K, Ito K, Iwatsubo T, et al. Phantom criteria for qualification of brain FDG and amyloid PET across different cameras. EJNMMI Phys. 2016;3(1):23. https:\/\/doi.org\/10.1186\/s40658-016-0159-y.","journal-title":"EJNMMI Phys"},{"issue":"3","key":"1792_CR25","doi-asserted-by":"publisher","first-page":"e2499","DOI":"10.1002\/brb3.2499","volume":"12","author":"H Matsuda","year":"2022","unstructured":"Matsuda H, Yamao T. Software development for quantitative analysis of brain amyloid PET. Brain Behav. 2022;12(3):e2499. https:\/\/doi.org\/10.1002\/brb3.2499.","journal-title":"Brain Behav"},{"issue":"1","key":"1792_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"4","key":"1792_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","volume":"39","author":"V Camus","year":"2012","unstructured":"Camus V, Payoux P, Barr\u00e9 L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39(4):621\u201331. https:\/\/doi.org\/10.1007\/s00259-011-2021-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1792_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11C] PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15(2):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.001.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1792_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):22. https:\/\/doi.org\/10.1186\/s13195-020-00587-5.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"1792_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669\u201378. https:\/\/doi.org\/10.1016\/S1474-4422(12)70142-4.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1792_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13(1):99. https:\/\/doi.org\/10.1186\/s13195-021-00836-1.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1792_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960\u20139. https:\/\/doi.org\/10.1097\/NEN.0b013e318232a379.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"24","key":"1792_CR33","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1212\/WNL.0000000000004733","volume":"89","author":"J Gonneaud","year":"2017","unstructured":"Gonneaud J, Arenaza-Urquijo EM, M\u00e9zenge F, Landeau B, Gaubert M, Bejanin A, et al. Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. Neurology. 2017;89(24):2438\u201346. https:\/\/doi.org\/10.1212\/WNL.0000000000004733.","journal-title":"Neurology"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-022-01792-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-022-01792-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T14:35:07Z","timestamp":1668609307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-022-01792-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s12149-022-01792-y","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Okita received research grants from PDRadiopharma.Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the certified Clinical Research Review Board at the National Center of Neurology and Psychiatry. This study was registered in the Japan Registry of Clinical Trials (jRCTs031180446).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects or their legal representatives gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}